\-\ Texto\\:\\ \ \(0\)\
\-\ cr\\ 2\\.4\\,\\ bun\\ 5\\.5\\ \\(baseline\\ cr\\ 1\\.6\\,\\ bun\\ 29\\)\ \(0\)\
\-\ ua\\-\\ 26\\ wbcs\\/hpf\\,\\ blood\\ 25\\/ul\\,\\ 2\\+\\ leukocyte\\ esterase\\ and\\ many\\ bacteria\\/hpf\ \(0\)\
\-\ the\\ patient\\ underwent\\ an\\ exploratory\\ laparotomy\\ with\\ resection\\ of\\ the\\ mass\\,\\ juxtarenal\\ ivc\\,\\ right\\ kidney\\,\\ and\\ right\\ adrenal\\ gland\\ with\\ graft\\ revision\\ of\\ the\\ juxtarenal\\ ivc\\.\\ \\ she\\ was\\ discharged\\ without\\ complication\\ on\\ post\\-operative\\ day\\ 5\\ with\\ scheduled\\ follow\\-up\\.\ \(0\)\
\-\ abdominal\\ ct\\ with\\ iv\\ contrast\\ reveals\\ a\\ 5x7x8cm\\ retroperitoneal\\ mass\\ at\\ the\\ level\\ of\\ the\\ juxtarenal\\ ivc\\ and\\ right\\ hydronephrosis\\.\\ \\ inferior\\ vena\\ caval\\ venography\\ reveals\\ total\\ ivc\\ occlusion\\ below\\ the\\ renal\\ veins\\ to\\ the\\ retrohepatic\\ region\\ with\\ significant\\ venous\\ collateralization\\.\ \(0\)\
\-\ pathology\\ consistent\\ with\\ leiomyosarcoma\\.\ \(0\)\
\-\ angiosarcoma\\,\\ leiomyosarcoma\\,\\ leiomyomatosis\\,\\ and\\ neurogenic\\ tumor\\ such\\ as\\ paraganglioma\ \(0\)\
\-\ 69\\ y\\/o\\ african\\-american\\ female\\ with\\ a\\ history\\ of\\ chronic\\ renal\\ insufficiency\\ and\\ hypertension\\ presented\\ with\\ a\\ 2\\ month\\ history\\ of\\ worsening\\ low\\ back\\ pain\\.\ \(0\)\
\-\ inferior\\ vena\\ cava\\ leiomyosarcoma\\ is\\ a\\ rare\\ tumor\\ representing\\ approximately\\ 0\\.5\\%\\ of\\ all\\ adult\\ soft\\ tissue\\ sarcomas\\.\\ \\ presenting\\ symptoms\\,\\ management\\,\\ and\\ prognosis\\ are\\ related\\ to\\ tumor\\ location\\.\\ \\ upper\\ ivc\\ leiomyosarcomas\\ occur\\ superior\\ to\\ the\\ hepatic\\ vein\\,\\ present\\ with\\ budd\\-chiari\\ syndrome\\,\\ and\\ are\\ the\\ least\\ amenable\\ to\\ resection\\ resulting\\ in\\ the\\ worst\\ prognosis\\.\\ \\ middle\\ ivc\\ leiomyosarcomas\\ occur\\ between\\ the\\ hepatic\\ and\\ renal\\ veins\\,\\ may\\ present\\ with\\ right\\ upper\\ quadrant\\ pain\\ or\\ renovascular\\ hypertension\\,\\ and\\ have\\ improved\\ survival\\.\\ \\ lower\\ ivc\\ leiomyosarcomas\\ occur\\ inferior\\ to\\ the\\ renal\\ vein\\,\\ may\\ present\\ with\\ right\\ lower\\ quadrant\\,\\ back\\,\\ or\\ flank\\ pain\\ or\\ lower\\ extremity\\ edema\\,\\ are\\ the\\ most\\ amenable\\ to\\ complete\\ resection\\,\\ and\\ have\\ the\\ best\\ prognosis\\.\\ \\ 5\\ year\\ survival\\ among\\ all\\ patients\\ has\\ been\\ reported\\ to\\ be\\ 33\\-53\\%\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ivc\\:\\ 0\\.394180367015701\ \(0\)\
\-\ juxtarenal\\:\\ 0\\.2782284850212058\ \(0\)\
\-\ leiomyosarcomas\\:\\ 0\\.2782284850212058\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.19666940305098532\ \(0\)\
\-\ the\\:\\ 0\\.16200281333307967\ \(0\)\
\-\ amenable\\:\\ 0\\.15490366897179628\ \(0\)\
\-\ prognosis\\:\\ 0\\.1531016239638095\ \(0\)\
\-\ renal\\:\\ 0\\.14445457892773764\ \(0\)\
\-\ occur\\:\\ 0\\.12795176525770766\ \(0\)\
\-\ with\\:\\ 0\\.1249124854137175\ \(0\)\
\-\ cr\\:\\ 0\\.12003714909473881\ \(0\)\
\-\ and\\:\\ 0\\.11983465429793423\ \(0\)\
\-\ inferior\\:\\ 0\\.11836000704407916\ \(0\)\
\-\ survival\\:\\ 0\\.11319575261685341\ \(0\)\
\-\ vena\\:\\ 0\\.11206586627679523\ \(0\)\
\-\ bun\\:\\ 0\\.11179293973478673\ \(0\)\
\-\ resection\\:\\ 0\\.1115220762240336\ \(0\)\
\-\ veins\\:\\ 0\\.10292579738911667\ \(0\)\
\-\ to\\:\\ 0\\.10148629189621439\ \(0\)\
\-\ right\\:\\ 0\\.09613476918992443\ \(0\)\
\-\ 5x7x8cm\\:\\ 0\\.09274282834040193\ \(0\)\
\-\ retrohepatic\\:\\ 0\\.09274282834040193\ \(0\)\
\-\ hepatic\\:\\ 0\\.09236479107017932\ \(0\)\
\-\ tumor\\:\\ 0\\.09100051874439474\ \(0\)\
\-\ present\\:\\ 0\\.08927369438937642\ \(0\)\
\-\ lower\\:\\ 0\\.0889028803001925\ \(0\)\
\-\ hypertension\\:\\ 0\\.08874477569707089\ \(0\)\
\-\ reveals\\:\\ 0\\.08822781423791323\ \(0\)\
\-\ leiomyomatosis\\:\\ 0\\.08569604384585021\ \(0\)\
\-\ renovascular\\:\\ 0\\.08569604384585021\ \(0\)\
\-\ vein\\:\\ 0\\.08313682197216685\ \(0\)\
\-\ caval\\:\\ 0\\.08157393916587417\ \(0\)\
\-\ quadrant\\:\\ 0\\.08124109691208509\ \(0\)\
\-\ venography\\:\\ 0\\.07745183448589814\ \(0\)\
\-\ collateralization\\:\\ 0\\.07745183448589814\ \(0\)\
\-\ back\\:\\ 0\\.07735380080998314\ \(0\)\
\-\ revision\\:\\ 0\\.07371341160613368\ \(0\)\
\-\ sarcomas\\:\\ 0\\.07296000320494297\ \(0\)\
\-\ esterase\\:\\ 0\\.0716024748567468\ \(0\)\
\-\ exploratory\\:\\ 0\\.06933391694933395\ \(0\)\
\-\ all\\:\\ 0\\.06904325298306344\ \(0\)\
\-\ leukocyte\\:\\ 0\\.06883789852496694\ \(0\)\
\-\ angiosarcoma\\:\\ 0\\.06883789852496694\ \(0\)\
\-\ of\\:\\ 0\\.06809339716435688\ \(0\)\
\-\ worst\\:\\ 0\\.0662829453113704\ \(0\)\
\-\ are\\:\\ 0\\.06601668820163636\ \(0\)\
\-\ laparotomy\\:\\ 0\\.06591321871039126\ \(0\)\
\-\ neurogenic\\:\\ 0\\.06307971763294933\ \(0\)\
\-\ paraganglioma\\:\\ 0\\.06307971763294933\ \(0\)\
\-\ pain\\:\\ 0\\.06225568356002662\ \(0\)\
\-\ upper\\:\\ 0\\.061980718622940786\ \(0\)\
\-\ baseline\\:\\ 0\\.06131817475567498\ \(0\)\
\-\ among\\:\\ 0\\.06131817475567498\ \(0\)\
\-\ 69\\:\\ 0\\.06086626208831536\ \(0\)\
\-\ or\\:\\ 0\\.06052380214282848\ \(0\)\
\-\ graft\\:\\ 0\\.060433585682219036\ \(0\)\
\-\ may\\:\\ 0\\.05836743249721445\ \(0\)\
\-\ have\\:\\ 0\\.057940991808184794\ \(0\)\
\-\ retroperitoneal\\:\\ 0\\.05589646986739336\ \(0\)\
\-\ insufficiency\\:\\ 0\\.05589646986739336\ \(0\)\
\-\ cava\\:\\ 0\\.05576181411013635\ \(0\)\
\-\ representing\\:\\ 0\\.054866083817982365\ \(0\)\
\-\ scheduled\\:\\ 0\\.05381947759376364\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.05381947759376364\ \(0\)\
\-\ adrenal\\:\\ 0\\.053709569917426356\ \(0\)\
\-\ least\\:\\ 0\\.05360083774679014\ \(0\)\
\-\ adult\\:\\ 0\\.0534932562027235\ \(0\)\
\-\ occlusion\\:\\ 0\\.05328144935323667\ \(0\)\
\-\ complication\\:\\ 0\\.05267128459718709\ \(0\)\
\-\ improved\\:\\ 0\\.051462898694558334\ \(0\)\
\-\ flank\\:\\ 0\\.05086720926552873\ \(0\)\
\-\ 29\\:\\ 0\\.05054185794689654\ \(0\)\
\-\ discharged\\:\\ 0\\.04977131041091681\ \(0\)\
\-\ resulting\\:\\ 0\\.048257302615184336\ \(0\)\
\-\ below\\:\\ 0\\.04775823991439256\ \(0\)\
\-\ total\\:\\ 0\\.04751760475018427\ \(0\)\
\-\ 26\\:\\ 0\\.04710973040821775\ \(0\)\
\-\ gland\\:\\ 0\\.04710973040821775\ \(0\)\
\-\ best\\:\\ 0\\.046662785422874636\ \(0\)\
\-\ many\\:\\ 0\\.04572368489954328\ \(0\)\
\-\ pathology\\:\\ 0\\.04552627362792683\ \(0\)\
\-\ presenting\\:\\ 0\\.045428987133898965\ \(0\)\
\-\ history\\:\\ 0\\.04431307802767045\ \(0\)\
\-\ mass\\:\\ 0\\.044303267305121116\ \(0\)\
\-\ worsening\\:\\ 0\\.04428549534482559\ \(0\)\
\-\ related\\:\\ 0\\.04407145878570278\ \(0\)\
\-\ rare\\:\\ 0\\.04377918187041981\ \(0\)\
\-\ management\\:\\ 0\\.04283645028768518\ \(0\)\
\-\ extremity\\:\\ 0\\.041769069362727486\ \(0\)\
\-\ reported\\:\\ 0\\.041769069362727486\ \(0\)\
\-\ middle\\:\\ 0\\.04146954770088613\ \(0\)\
\-\ iv\\:\\ 0\\.04143680576906027\ \(0\)\
\-\ venous\\:\\ 0\\.04140416894795079\ \(0\)\
\-\ kidney\\:\\ 0\\.04074193928389382\ \(0\)\
\-\ complete\\:\\ 0\\.04065076054676008\ \(0\)\
\-\ location\\:\\ 0\\.04038203051182305\ \(0\)\
\-\ underwent\\:\\ 0\\.03994935410572674\ \(0\)\
\-\ superior\\:\\ 0\\.037703413251122586\ \(0\)\
\-\ between\\:\\ 0\\.037680796198313896\ \(0\)\
\-\ such\\:\\ 0\\.03730381050309954\ \(0\)\
\-\ approximately\\:\\ 0\\.03700351640412936\ \(0\)\
\-\ day\\:\\ 0\\.03694030566549973\ \(0\)\
\-\ month\\:\\ 0\\.03527758253364404\ \(0\)\
\-\ level\\:\\ 0\\.035030899625787405\ \(0\)\
\-\ syndrome\\:\\ 0\\.03496150440040455\ \(0\)\
\-\ region\\:\\ 0\\.03468856556348462\ \(0\)\
\-\ edema\\:\\ 0\\.034588073532288606\ \(0\)\
\-\ she\\:\\ 0\\.03452162649153172\ \(0\)\
\-\ chronic\\:\\ 0\\.03442276320633442\ \(0\)\
\-\ presented\\:\\ 0\\.033818012611331195\ \(0\)\
\-\ been\\:\\ 0\\.03378715868463096\ \(0\)\
\-\ blood\\:\\ 0\\.03367990143157519\ \(0\)\
\-\ significant\\:\\ 0\\.033483662683003054\ \(0\)\
\-\ low\\:\\ 0\\.033276480760904115\ \(0\)\
\-\ patients\\:\\ 0\\.03262402174732963\ \(0\)\
\-\ symptoms\\:\\ 0\\.031730277913196984\ \(0\)\
\-\ abdominal\\:\\ 0\\.03171770356274484\ \(0\)\
\-\ consistent\\:\\ 0\\.031444931171920036\ \(0\)\
\-\ soft\\:\\ 0\\.030874038122061825\ \(0\)\
\-\ without\\:\\ 0\\.030588927988883366\ \(0\)\
\-\ tissue\\:\\ 0\\.030421622605138875\ \(0\)\
\-\ most\\:\\ 0\\.03018111682674579\ \(0\)\
\-\ contrast\\:\\ 0\\.0281774311919027\ \(0\)\
\-\ female\\:\\ 0\\.02798411513123569\ \(0\)\
\-\ has\\:\\ 0\\.026489340175353485\ \(0\)\
\-\ be\\:\\ 0\\.023525288512226347\ \(0\)\
\-\ as\\:\\ 0\\.023297694621395786\ \(0\)\
\-\ an\\:\\ 0\\.022176184162063194\ \(0\)\
\-\ ct\\:\\ 0\\.02207833585095112\ \(0\)\
\-\ at\\:\\ 0\\.021904547669569282\ \(0\)\
\-\ was\\:\\ 0\\.020211003080362933\ \(0\)\
\-\ patient\\:\\ 0\\.018862088789938152\ \(0\)\
\-\ year\\:\\ 0\\.01787218446426251\ \(0\)\
\-\ on\\:\\ 0\\.01751476740962136\ \(0\)\
\-\ is\\:\\ 0\\.015881673662305987\ \(0\)\
\-\ in\\:\\ 0\\.014426682368240936\ \(0\)\
